While MK-2206 is currently undergoing clinical evaluation for various cancers [16, 25], the AKT inhibitor capivasertib, developed by AstraZeneca, received EMA approval for the treatment of breast cancer in 2024. This evidence concerns the gene AKT1 and breast carcinoma.